What question did this study set out to answer?

This research aims to evaluate the effects of GLP-1RA and GLP-1/GIPRA on glycemic control and weight in youth with type 1 diabetes, and identify characteristics of nonresponders.

June 7, 2026Diabetes

2100-P: Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA) or GLP-1RA/Glucose-Dependent Insulinotropic Polypeptide RA (GLP-1/GIPRA) Effects in Youth/Young Adults (Y/YA) with Type 1 Diabetes and Characteristics of Nonresponders

View Full Paper

Ask AI

Bookmark

Authors

LWLAUREN A. WATERMANThe Medical Center of Aurora KNKristen J. NadeauGeneral / Preventive / Lipids HAHALIS K. AKTURKThe Medical Center of Aurora

Discussion

Member takes

Implication

Randomized trial finds GLP-1RA and GLP-1/GIPRA improve glycemia and weight in youth with T1D, suggesting potential benefits for further exploration.

Key Points

This research aims to evaluate the effects of GLP-1RA and GLP-1/GIPRA on glycemic control and weight in youth with type 1 diabetes, and identify characteristics of nonresponders.
Review of Y/YA with T1D treated with GLP-1RA or GLP-1/GIPRA.
Data collected on demographics, BMI, A1c, insulin dosing, and adverse events over 18 months.
Statistical analysis using Student’s t-test and chi-square tests.
GLP-1RA or GLP-1/GIPRA treatment led to significant improvements in glycemia and weight along with reduced insulin dosage (p<0.05).
32% of participants were non-responders, with non-response linked to obesity onset prior to puberty (p=0.0275) and limited to a single form of GLP-1RA or GLP-1/GIPRA (p=0.004).

Cite This Study

WATERMAN et al. (2026) studied this question.

synapsesocial.com/papers/6a250be87def13d035e1bf7a https://doi.org/10.2337/db26-2100-p

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial finds GLP-1RA and GLP-1/GIPRA improve glycemia and weight in youth with T1D, suggesting potential benefits for further exploration.

2100-P: Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA) or GLP-1RA/Glucose-Dependent Insulinotropic Polypeptide RA (GLP-1/GIPRA) Effects in Youth/Young Adults (Y/YA) with Type 1 Diabetes and Characteristics of Nonresponders

Discussion

Member takes

Implication

Key Points

Cite This Study

2100-P: Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA) or GLP-1RA/Glucose-Dependent Insulinotropic Polypeptide RA (GLP-1/GIPRA) Effects in Youth/Young Adults (Y/YA) with Type 1 Diabetes and Characteristics of Nonresponders

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider